| For: | Raschi E, Poluzzi E, Koci A, Caraceni P, Ponti FD. Assessing liver injury associated with antimycotics: Concise literature review and clues from data mining of the FAERS database. World J Hepatol 2014; 6(8): 601-612 [PMID: 25232453 DOI: 10.4254/wjh.v6.i8.601] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v6/i8/601.htm |
| Number | Citing Articles |
| 1 |
Franziska Wewering, Florent Jouy, Dirk K. Wissenbach, Scarlett Gebauer, Matthias Blüher, Rolf Gebhardt, Ralph Pirow, Martin von Bergen, Stefan Kalkhof, Andreas Luch, Sebastian Zellmer. Characterization of chemical-induced sterile inflammation in vitro: application of the model compound ketoconazole in a human hepatic co-culture system. Archives of Toxicology 2017; 91(2) doi: 10.1007/s00204-016-1686-y
|
| 2 |
Emanuel Raschi, Elisabetta Poluzzi, Fabrizio De Ponti. Comment on: “Pharmacokinetics in Patients with Chronic Liver Disease and Hepatic Safety of Incretin-Based Therapies for the Management of Type 2 Diabetes Mellitus”. Clinical Pharmacokinetics 2015; 54(4) doi: 10.1007/s40262-015-0248-4
|
| 3 |
Patrizia Haegler, Lorenz Joerin, Stephan Krähenbühl, Jamal Bouitbir. Hepatocellular Toxicity of Imidazole and Triazole Antimycotic Agents. Toxicological Sciences 2017; 157(1) doi: 10.1093/toxsci/kfx029
|
| 4 |
David J. Greenblatt. The Pharmacovigilance Syndrome. Journal of Clinical Psychopharmacology 2015; 35(4) doi: 10.1097/JCP.0000000000000367
|
| 5 |
Gemma Hayes, Lilyann Novak-Frazer. Chronic Pulmonary Aspergillosis—Where Are We? and Where Are We Going?. Journal of Fungi 2016; 2(2) doi: 10.3390/jof2020018
|
| 6 |
Lydia L. Benitez, Peggy L. Carver. Adverse Effects Associated with Long-Term Administration of Azole Antifungal Agents. Drugs 2019; 79(8) doi: 10.1007/s40265-019-01127-8
|
| 7 |
Meng Zhu, Linghui Tao, Feiye Zhu, Yongsheng Zhang. A Comparative Analysis of ADRs under Obeticholic Acid and
Ursodeoxycholic Acid in Cholestatic Liver Diseases Using the FAERS
Database. Drug Research 2024; 74(09) doi: 10.1055/a-2401-4700
|
| 8 |
Emanuel Raschi, Fabrizio De Ponti. Drug- and herb-induced liver injury: Progress, current challenges and emerging signals of post-marketing risk. World Journal of Hepatology 2015; 7(13): 1761-1771 doi: 10.4254/wjh.v7.i13.1761
|
| 9 |
Matheus Alexandre Da Silva Taliari, Andressa Costa Fontes, Fellipe Genasculi Araujo, Luis Lênin Vicente Pereira, Luciana Estevam Simonato, José Martins Pinto Neto, André Wilian Lozano, Nilton Cesar Pezati Boer, Wagner Rafael Da Silva, Rafael Guerra De Aquino, Farid Jamil Silva De Arruda, Fábio Zanusso Prates, Noedi Leoni De Freitas, Jean Donizete Silveira Taliari, Rogério Rodrigo Ramos. Protoporphyrin IX Associated with Visible Light for the Treatment of Trichophyton rubrum Causing Onychomycosis - An Updated Review. International Journal for Innovation Education and Research 2022; 10(6) doi: 10.31686/ijier.vol10.iss6.3774
|
| 10 |
Zhi-Xuan Zhou, Xue-Dong Yin, Yu Zhang, Qi-Hui Shao, Xin-Yu Mao, Wen-Juan Hu, Yun-Lin Shen, Bin Zhao, Zhi-Ling Li. Antifungal Drugs and Drug-Induced Liver Injury: A Real-World Study Leveraging the FDA Adverse Event Reporting System Database. Frontiers in Pharmacology 2022; 13 doi: 10.3389/fphar.2022.891336
|
| 11 |
Qiang Shi, Xi Yang, James J. Greenhaw, Alec Thomas Salminen, Gary M. Russotti, William F. Salminen. Drug-Induced Liver Injury in Children: Clinical Observations, Animal Models, and Regulatory Status. International Journal of Toxicology 2017; 36(5) doi: 10.1177/1091581817721675
|
| 12 |
Aditya K. Gupta, Kelly A. Foley, Sarah G. Versteeg. New Antifungal Agents and New Formulations Against Dermatophytes. Mycopathologia 2017; 182(1-2) doi: 10.1007/s11046-016-0045-0
|
| 13 |
Andreas H Groll, Bart J A Rijnders, Thomas J Walsh, Jill Adler-Moore, Russell E Lewis, Roger J M Brüggemann. Clinical Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Liposomal Amphotericin B. Clinical Infectious Diseases 2019; 68(Supplement_4) doi: 10.1093/cid/ciz076
|
| 14 |
Noémi Outeiro, Nicolas Hohmann, Gerd Mikus. No Increased Risk of Ketoconazole Toxicity in Drug–Drug Interaction Studies. The Journal of Clinical Pharmacology 2016; 56(10) doi: 10.1002/jcph.795
|
| 15 |
Mohamed Kadry Taher, Abdallah Alami, Christopher A. Gravel, Derek Tsui, Lise M. Bjerre, Franco Momoli, Donald R. Mattison, Daniel Krewski. Systemic quinolones and risk of acute liver failure I: Analysis of data from the US FDA adverse event reporting system. JGH Open 2021; 5(7) doi: 10.1002/jgh3.12585
|
| 16 |
Nikolaos Spernovasilis, Diamantis P. Kofteridis. Pre-Existing Liver Disease and Toxicity of Antifungals. Journal of Fungi 2018; 4(4) doi: 10.3390/jof4040133
|
| 17 |
Zainab M. Mahdi, Uta Synal-Hermanns, Aylin Yoker, Kaspar P. Locher, Bruno Stieger. Role of Multidrug Resistance Protein 3 in Antifungal-Induced Cholestasis. Molecular Pharmacology 2016; 90(1) doi: 10.1124/mol.116.103390
|
| 18 |
Shahid Habib. Recent Advances in Liver Cirrhosis Related Complications. 2025; doi: 10.1016/B978-0-443-21938-2.00016-3
|
| 19 |
Emilie Faway, Cindy Staerck, Célya Danzelle, Sophie Vroomen, Christel Courtain, Bernard Mignon, Yves Poumay. Towards a Standardized Procedure for the Production of Infective Spores to Study the Pathogenesis of Dermatophytosis. Journal of Fungi 2021; 7(12) doi: 10.3390/jof7121029
|
| 20 |
Madhura Roy, Sonali Karhana, Md Shamsuzzaman, Mohd. Ashif Khan. Recent drug development and treatments for fungal infections. Brazilian Journal of Microbiology 2023; 54(3) doi: 10.1007/s42770-023-00999-z
|
| 21 |
Harshad Devarbhavi, Herbert L. Bonkovsky, Mark Russo, Naga Chalasani. Zakim and Boyer's Hepatology. 2018; doi: 10.1016/B978-0-323-37591-7.00056-2
|
| 22 |
Aditya K. Gupta, Rachel R. Mays, Sarah G. Versteeg, Neil H. Shear, Vincent Piguet. Update on current approaches to diagnosis and treatment of onychomycosis. Expert Review of Anti-infective Therapy 2018; 16(12) doi: 10.1080/14787210.2018.1544891
|
| 23 |
Nadim Khalil, Jennifer L Kasten, Rebecca A Marsh, Lara Danziger-Isakov. Multifocal Trichosporon asahii Infection in a Patient With Chronic Granulomatous Disease. Journal of the Pediatric Infectious Diseases Society 2022; 11(10) doi: 10.1093/jpids/piac064
|
| 24 |
David J. Greenblatt. Evidence‐based choice of ritonavir as index CYP3A inhibitor in drug‐drug interaction studies. The Journal of Clinical Pharmacology 2016; 56(2) doi: 10.1002/jcph.609
|
| 25 |
David J. Greenblatt, Gerd Mikus. Ketoconazole and Liver Injury: A Five‐Year Update. Clinical Pharmacology in Drug Development 2019; 8(1) doi: 10.1002/cpdd.652
|
| 26 |
Rachel Gallant, Phillip Bonney, Leigh Peek, Zhongxin Yu, David Crawford. Voriconazole‐induced hepatotoxicity following the administration of PEG‐asparaginase: Case report. Pediatric Blood & Cancer 2017; 64(6) doi: 10.1002/pbc.26293
|
| 27 |
Mohamed Kadry Taher, Abdallah Alami, Christopher A. Gravel, Derek Tsui, Lise M. Bjerre, Franco Momoli, Donald Mattison, Daniel Krewski. Systemic quinolones and risk of retinal detachment I: analysis of data from the US FDA adverse event reporting system. Expert Opinion on Drug Safety 2022; 21(2) doi: 10.1080/14740338.2022.1993187
|
| 28 |
Andrea M. Burden, Lucy Hausammann, Alessandro Ceschi, Hugo Kupferschmidt, Stefan Weiler. Observational cross-sectional case study of toxicities of antifungal drugs. Journal of Global Antimicrobial Resistance 2022; 29 doi: 10.1016/j.jgar.2021.11.010
|
| 29 |
Alicia Moreno‐Sabater, Nacéra Ouali, François Chasset, Camille Frances, Patricia Senet, Caroline Faucon, Christophe Hennequin, Claude Bachmeyer. Severe onychomycosis management with oral terbinafine in a kidney transplantation setting: Clinical follow‐up by image analysis. Mycoses 2021; 64(3) doi: 10.1111/myc.13220
|
| 30 |
Maria Clara Padovani de Souza, Andrezza Gouvêa dos Santos, Adriano Max Moreira Reis. Adverse Drug Reactions in Patients Receiving Systemic Antifungal Therapy at a High‐Complexity Hospital. The Journal of Clinical Pharmacology 2016; 56(12) doi: 10.1002/jcph.772
|
| 31 |
A.K. Gupta, J. Carviel, M.A. MacLeod, N. Shear. Assessing finasteride‐associated sexual dysfunction using theFAERSdatabase. Journal of the European Academy of Dermatology and Venereology 2017; 31(6) doi: 10.1111/jdv.14223
|
| 32 |
Harshad Devarbhavi. Acute Liver Failure Induced by Anti-infectious Drugs: Causes and Management. Current Hepatology Reports 2017; 16(4) doi: 10.1007/s11901-017-0367-5
|
| 33 |
Bianca Raluca Maris, Alina Grama, Tudor Lucian Pop. Drug-Induced Liver Injury—Pharmacological Spectrum Among Children. International Journal of Molecular Sciences 2025; 26(5) doi: 10.3390/ijms26052006
|
| 34 |
Frank P. Tverdek, Diamantis Kofteridis, Dimitrios P. Kontoyiannis. Antifungal agents and liver toxicity: a complex interaction. Expert Review of Anti-infective Therapy 2016; 14(8) doi: 10.1080/14787210.2016.1199272
|
| 35 |
Nancy H.C. Loos, Jos H. Beijnen, Alfred H. Schinkel. The inhibitory and inducing effects of ritonavir on hepatic and intestinal CYP3A and other drug-handling proteins. Biomedicine & Pharmacotherapy 2023; 162 doi: 10.1016/j.biopha.2023.114636
|
| 36 |
Viktorija O. Barr, Elizabeth G. Zdyb, Michael Postelnick. The Clinical Significance of Azole Antifungals’ Effects on the Liver and Transaminase Levels. Current Fungal Infection Reports 2015; 9(3) doi: 10.1007/s12281-015-0226-1
|
| 37 |
Felix Bongomin, Isabel Rodriguez-Goncer, Carol Lorden, Akaninyene Otu, Rohit Bazaz. Late-onset isavuconazole-induced liver injury. Medical Mycology Case Reports 2018; 22 doi: 10.1016/j.mmcr.2018.07.006
|
| 38 |
Amin Rakhshan, Bardia Rahmati Kamel, Ali Saffaei, Maria Tavakoli-Ardakani. Hepatotoxicity Induced by Azole Antifungal Agents: A Review Study. Iranian Journal of Pharmaceutical Research 2023; 22(1) doi: 10.5812/ijpr-130336
|
| 39 |
B.S. Navarro, M.E. Auler, R.L.O. Dos Santos, L. da Silva Ruiz, D.C. Nascimento, P.A.N. Felippe, C. Domaneschi, D. Moreira, F.A. Baroni, M.F.C. Pires, C.R. Paula. Antifungal sensitivity and species of yeasts in oral mucosa of street mixed-breed dogs. Journal de Mycologie Médicale 2020; 30(4) doi: 10.1016/j.mycmed.2020.101010
|
| 40 |
Adam Lavertu, Bianca Vora, Kathleen M. Giacomini, Russ Altman, Stefano Rensi. A New Era in Pharmacovigilance: Toward Real‐World Data and Digital Monitoring. Clinical Pharmacology & Therapeutics 2021; 109(5) doi: 10.1002/cpt.2172
|
| 41 |
Rose O’Flynn, Yun-Ping Zhou, Hetty Waskin, Ronald Leong, Walter Straus. Hepatic safety of the antifungal triazole agent posaconazole: characterization of adverse event reports in a manufacturer’s safety database. Expert Opinion on Drug Safety 2022; 21(8) doi: 10.1080/14740338.2022.2047177
|
| 42 |
Hong Ye, Shari R. Lipner. Antifungals for onychomycosis and risk of liver injury: A retrospective cohort study using TriNetX. Journal of the American Academy of Dermatology 2026; 94(4) doi: 10.1016/j.jaad.2025.11.058
|
| 43 |
Robert John Fontana, Elizabeth Theresa Cirulli, Jiezhun Gu, David Kleiner, David Ostrov, Elizabeth Phillips, Ryan Schutte, Huiman Barnhart, Naga Chalasani, Paul Brent Watkins, Jay H. Hoofnagle. The role of HLA-A*33:01 in patients with cholestatic hepatitis attributed to terbinafine. Journal of Hepatology 2018; 69(6) doi: 10.1016/j.jhep.2018.08.004
|
| 44 |
Minje Park, Anita Carson, Rena Conti. Linking Medication Errors to Supply Chain Disruptions: Evidence from Heparin Shortages Caused by Hurricane Maria. SSRN Electronic Journal 2023; doi: 10.2139/ssrn.4472407
|
| 45 |
Tim Bühler, Michael Medinger, Jamal Bouitbir, Stephan Krähenbühl, Anne Leuppi-Taegtmeyer. Hepatotoxicity Due to Azole Antimycotic Agents in a HLA B*35:02-Positive Patient. Frontiers in Pharmacology 2019; 10 doi: 10.3389/fphar.2019.00645
|
| 46 |
Payal Rana, Michael D. Aleo, Xuerong Wen, Stephen Kogut. Hepatotoxicity reports in the FDA adverse event reporting system database: A comparison of drugs that cause injury via mitochondrial or other mechanisms. Acta Pharmaceutica Sinica B 2021; 11(12) doi: 10.1016/j.apsb.2021.05.028
|
| 47 |
M.A. Gupta, B. Vujcic, A.D. Sheridan, A.K. Gupta. Reduced risk of suicidal behaviours associated with the treatment of hidradenitis suppurativa with tumour necrosis factor alpha antagonists: results from the US FDA Adverse Events Reporting System pharmacovigilance database. Journal of the European Academy of Dermatology and Venereology 2020; 34(7) doi: 10.1111/jdv.16224
|
| 48 |
Peymaan S. Banankhah, Kyle A. Garnick, David J. Greenblatt. Ketoconazole‐Associated Liver Injury in Drug‐Drug Interaction Studies in Healthy Volunteers. The Journal of Clinical Pharmacology 2016; 56(10) doi: 10.1002/jcph.711
|
| 49 |
Emanuel Raschi, Elisabetta Poluzzi, Ariola Koci, Francesco Salvo, Antoine Pariente, Maurizio Biselli, Ugo Moretti, Nicholas Moore, Fabrizio De Ponti. Liver injury with novel oral anticoagulants: assessing post‐marketing reports in the US Food and Drug Administration adverse event reporting system. British Journal of Clinical Pharmacology 2015; 80(2) doi: 10.1111/bcp.12611
|
| 50 |
Emilie Faway, Marc Thiry, Bernard Mignon, Yves Poumay. Dermatophytes and Dermatophytoses. 2021; doi: 10.1007/978-3-030-67421-2_7
|
| 51 |
Fatma Etgü. Retrospective Analysis of Liver Enzyme Abnormalities in Patients Prescribed Terbinafine and Itraconazole for Onychomycosis . Cureus 2023; doi: 10.7759/cureus.44914
|
| 52 |
Sana Kauser, Mehak Gulzar, Gulam Mustafa Hasan, Pritam Kumar. Exploring fungal survival mechanisms: toward next-generation antifungal therapies against Candida spp.. Archives of Microbiology 2025; 207(11) doi: 10.1007/s00203-025-04519-5
|
| 53 |
Jackson Thomas, Gregory M. Peterson, Julia K. Christenson, Sam Kosari, Kavya E. Baby. Antifungal Drug Use for Onychomycosis. American Journal of Therapeutics 2019; 26(3) doi: 10.1097/MJT.0000000000000696
|
| 54 |
Minje Park, Anita L. Carson, Rena M. Conti. Linking Medication Errors to Drug Shortages: Evidence from Heparin Supply Chain Disruptions Caused by Hurricane Maria. Manufacturing & Service Operations Management 2025; 27(4) doi: 10.1287/msom.2023.0297
|
| 55 |
Özge AKÇAY, Mukaddes GÜMÜŞTEKİN. Voriconazole-Induced Hepatotoxicity Concise up-to-date review. Journal of Basic and Clinical Health Sciences 2022; 6(1) doi: 10.30621/jbachs.1051669
|
| 56 |
Ioannis Kyriakidis, Athanasios Tragiannidis, Silke Munchen, Andreas H. Groll. Clinical hepatotoxicity associated with antifungal agents. Expert Opinion on Drug Safety 2016; doi: 10.1080/14740338.2017.1270264
|
| 57 |
A.K. Gupta, J. Carviel, M.A. Gupta, N.H. Shear. Assessing dutasteride‐associated sexual dysfunction using the U.S. Food and Drug Administration Adverse Event Reporting System. Journal of the European Academy of Dermatology and Venereology 2018; 32(8) doi: 10.1111/jdv.14728
|
| 58 |
Aditya K. Gupta, Sarah G. Versteeg, Neil H. Shear. Confirmatory Testing Prior to Initiating Onychomycosis Therapy Is Cost-Effective. Journal of Cutaneous Medicine and Surgery 2018; 22(2) doi: 10.1177/1203475417733461
|
| 59 |
Ippazio Cosimo Antonazzo, Elisabetta Poluzzi, Emanuele Forcesi, Trond Riise, Kjetil Bjornevik, Elisa Baldin, Luigi Muratori, Fabrizio De Ponti, Emanuel Raschi. Liver injury with drugs used for multiple sclerosis: A contemporary analysis of the FDA Adverse Event Reporting System. Multiple Sclerosis Journal 2019; 25(12) doi: 10.1177/1352458518799598
|
| 60 |
Bhavana Rajbanshi, Liangliang Shen, Miao Jiang, Qingyu Gao, Xin Huang, Jiaoyang Ma, Jihong Wang, Yang Hu, Hongli Lv, Xiao Wu, Jingjun Zhao. Comparative Study of Traditional Ablative CO2 Laser-Assisted Topical Antifungal with only Topical Antifungal for Treating Onychomycosis: A Multicenter Study. Clinical Drug Investigation 2020; 40(6) doi: 10.1007/s40261-020-00914-6
|
| 61 |
David J. Greenblatt, Jerold S. Harmatz. Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450‐3A in drug–drug interaction studies. British Journal of Clinical Pharmacology 2015; 80(3) doi: 10.1111/bcp.12668
|
| 62 |
Miriam T. Levine, Pranatharthi H. Chandrasekar. Adverse effects of voriconazole: Over a decade of use. Clinical Transplantation 2016; 30(11) doi: 10.1111/ctr.12834
|
| 63 |
Romeo-Gabriel Mihăilă. Voriconazole and the liver. World Journal of Hepatology 2015; 7(14): 1828-1833 doi: 10.4254/wjh.v7.i14.1828
|
| 64 |
Vincent Lo Re, Dean M. Carbonari, James D. Lewis, Kimberly A. Forde, David S. Goldberg, K. Rajender Reddy, Kevin Haynes, Jason A. Roy, Daohang Sha, Amy R. Marks, Jennifer L. Schneider, Brian L. Strom, Douglas A. Corley. Oral Azole Antifungal Medications and Risk of Acute Liver Injury, Overall and by Chronic Liver Disease Status. The American Journal of Medicine 2016; 129(3) doi: 10.1016/j.amjmed.2015.10.029
|